Author: claimsbot

1. A harness for use with breathing equipment, the harness comprising
at least one shoulder support panel; and
a belt portion, the belt portion comprising
attachment means for attaching a cylinder of breathable gas to the belt portion, the attachment means comprising mounting means for releasably engaging a mounting portion of the cylinder, and
retaining means for retaining a retaining device for the cylinder,

wherein the cylinder may be attached to the belt portion such that, without disruption of the breathable gas, the cylinder may be alternated between first and second configurations second configurations,
wherein in the first configuration the cylinder is attached to the belt portion by both the mounting means and the retaining means, and
wherein in the second configuration the cylinder is attached to the belt portion by the retaining means alone, and

wherein the shoulder support panel is adapted to be arranged in use to pass around a wearer over one shoulder in the manner of a bandolier or sash, and the belt portion is adapted to be arranged in use to pass around the waist of the wearer.
2. A harness according to claim 1, wherein the mounting means includes a flexible mounting plate for receiving a cylinder of breathing gas.
3. A harness according to claim 2, wherein the mounting plate is of moulded material.
4. A harness according to claim 2, wherein the mounting plate is moulded so as to include one or more recessed portions for receiving one or more components of breathing apparatus.
5. A harness according to claim 2, wherein the shoulder panel is flexible and wherein the shoulder panel and mounting plate are of a composite material.
6. A harness according to claim 5, wherein the composite material comprises foam, which may be a closed-cell, open-face foam, such as compression-moulded EVA foam.
7. A harness according to claim 2, wherein the shoulder panel and mounting plate comprise a sandwich construction.
8. A harness according to claim 7, wherein shoulder panel and mounting plate comprise two layers of foam enclosing or encapsulating a layer of stiffer material therebetween.
9. A harness according to claim 2, wherein the shoulder panel and mounting plate comprises a single layer of foam sandwiched between two layers of stiffer material.
10. A harness according to claim 1, wherein when a cylinder is attached to the belt portion by both the mounting means and the retaining means, the cylinder and belt portion are juxtaposed in the first configuration, and when the cylinder is attached to the belt portion by only the retaining means, the cylinder and belt portion are loosely attached in the second configuration.
11. A harness according to claim 1, wherein when, in use, the cylinder and belt portion are retained in the second configuration a user is able to move the cylinder freely about his person whilst retaining attachment to the cylinder by the retaining means.
12. A harness according to claim 1, wherein the retaining means comprises one or more retaining straps and the retaining portion of the cylinder comprises a web, holster or cradle for holding the cylinder.
13. A harness according to claim 1, wherein the belt portion includes a flexible hip-plate arranged for location on a hip of a wearer, and at least two connectors for connecting the cylinder of breathable gas thereto, wherein a first connector is arranged for connecting the cylinder detachably, a second connector is arranged for connecting the cylinder non-detachably, the detachable connector being arranged to hold the cylinder connected thereto in close proximity to the hip-plate, and the non-detachable connector being arranged to hold the cylinder connected thereto between the legs of a user when the detachable connector between the harness and the cylinder is detached.
14. A harness according to claim 13, wherein the cylinder has a manifold, in which the manifold includes a port for connecting a breathing-gas line from the cylinder to a face mask and in which the manifold further includes a connector for connecting the breathing apparatus to an additional fluid supply line.
15. A harness for use with breathing equipment, the harness comprising
at least one shoulder support panel adapted to be arranged in use to pass around a wearer over one shoulder in the manner of a bandolier or sash; and
a belt portion adapted to be arranged in use to pass around the waist of the wearer, the belt portion comprising,
attachment means for attaching a cylinder of breathable gas to the belt portion, the attachment means comprising mounting means for releasably engaging a mounting portion of the cylinder, and
a retaining strap coupled to the cylinder, the retaining strap extendable to remaining coupled to the cylinder without disruption of breathable gas when both the mounting portion of the cylinder is disengaged from the mounting means and the cylinder is displaced to a location remote from the belt portion of the harness.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1-20. (canceled)
21. A compound having the following formula (I):
or a salt thereof, wherein:
R1 is H, trityl or the 5\u2032 terminal phosphorous of a morpholino oligomer;
R2 is H or
and
R3 is H or a linkage to a solid support.
22. The compound of claim 21, wherein R1 is trityl or the 5\u2032 terminal phosphorous of a morpholino oligomer and R2 is H.
23. The compound of claim 22, wherein the compound has the following structure:
24. The compound of claim 22, wherein the compound has the following structure:
wherein P1 represents the 5\u2032 terminal phosphorous atom of a morpholino oligomer.
25. The compound of claim 24, wherein the compound has the following structure:
wherein:
B is a base pairing moiety; and
P2 represents the 5\u2032 phosphorous of an adjacent morpholino subunit.
26. The compound of claim 21, wherein R2 is
27. The compound of claim 26, wherein the compound has the following structure:
28. The compound of claim 26, wherein the compound has the following structure:
wherein R3 is a linkage to a solid support.
29. The compound of claim 26, wherein the compound has the following structure:
wherein R3 is a linkage to a solid support.
30. The compound of claim 26, wherein the compound has the following structure:
wherein:
P1 represents the 5\u2032 terminal phosphorous atom of a morpholino oligomer; and
R3 is a linkage to a solid support.
31. The compound of claim 30, wherein the compound has the following structure:
wherein:
B is a base pairing moiety;
P2 represents the 5\u2032 phosphorous of an adjacent morpholino subunit; and
R3 is a linkage to a solid support.
32. The compound of claim 21, wherein the solid support comprises aminomethylpolystyrene.
33. A morpholino oligomer comprising the following structure:
wherein P1 represents the 5\u2032 terminal phosphorous atom of the morpholino oligomer.
34. The morpholino oligomer of claim 33, wherein the morpholino oligomer has the following structure:
wherein:
B is a base pairing moiety; and
P2 represents the 5\u2032 phosphorous of an adjacent morpholino subunit.
35. The morpholino oligomer of claim 33, wherein the morpholino oligomer comprises subunits having the following structure:
wherein:
each X is at, each occurrence, independently alkyl, alkoxy, thioalkoxy, \u2014NR2 or 1-piperazino, wherein at least one of the X moieties in the oligomer is 1-piperazino;

each R is, at each occurrence, independently hydrogen or lower alkyl; and
each B is, at each occurrence, independently a purine or pyrimidine base-pairing moiety.
36. The morpholino oligomer of claim 35, wherein each X that is not 1-piperazino is \u2014NR2, wherein each R is methyl.
37. A solid support covalently bound to a compound having the following structure:
wherein:
R1 is H, trityl or the 5\u2032 terminal phosphorous of a morpholino oligomer; and
R3 is a linkage to the solid support.
38. The solid support of claim 37, wherein R1 is H.
39. The solid support of claim 37, wherein R1 is trityl.
40. The solid support of claim 37, wherein R1 is the 5\u2032 terminal phosphorous of a morpholino oligomer.
41. The solid support of claim 37, wherein the solid support comprises aminomethylpolystyrene.

1. A method comprising:
receiving an integrated circuit (IC) design layout;
generating a gray map from the IC design layout;
generating an edge map from the IC design layout, wherein the edge map is generated using vertex information from the IC design layout; and
modifying the IC design layout based on the gray map and the edge map.
2. The method of claim 1 wherein:
the IC design layout has a first pixel size; and
the modifying the IC design layout based on the gray map and the edge map includes increasing the first pixel size of the IC design layout to a second pixel size.
3. The method of claim 1 wherein the receiving the IC design layout includes receiving an electron proximity correction (EPC) modified IC design layout.
4. The method of claim 1 further including using the modified IC design layout to write a pattern on a substrate, wherein the pattern corresponds with a pattern of the IC design layout.
5. The method of claim 1 wherein the generating the edge map using vertex information from the IC design layout includes:
generating a vertex map from the IC design layout; and
generating the edge map based on the vertex map.
6. The method of claim 1 wherein generating the vertex information is associated with features of the IC design layout.
7. The method of claim 6 wherein the features of the IC design layout are polygons.
8. A method comprising:
receiving an integrated circuit (IC) design layout;
modifying the IC design layout using an electron proximity correction (EPC) technique;
dithering the EPC modified IC design layout, wherein the dithering includes:
generating a vertex map and a gray map from the EPC modified IC design layout,
generating an edge map based on the vertex map, and
generating a dithered, EPC modified IC design layout based on the gray map and the edge map; and

converting the dithered, EPC modified IC design layout into an electron beam writer format data.
9. The method of claim 8 further comprising writing the electron beam writer format data on a substrate.
10. The method of claim 9, wherein writing the electron beam writer format includes exposing a resist film coated on the substrate to an electron beam, such that a pattern of a layer of an IC is formed in the resist film.
11. The method of claim 8 wherein the EPC modified IC design layout has a first pixel size and the dithered EPC modified IC design layout has a second pixel size that is larger than the first pixel size.
12. The method of claim 8 further comprising flattening the IC design layout before modifying the IC design layout using the EPC technique.
13. The method of claim 12 wherein flattening the IC design layout data includes decomposing the IC design layout into primitive patterns and eliminating any overlap of the primitive patterns.
14. The method of claim 12 further comprising striping the IC design layout before modifying the IC design layout using the EPC technique.
15. The method of claim 14, wherein the striping includes dividing the EPC modified IC design layout into a plurality of sub-fields, and further dividing the sub-fields into a plurality of sub-sub-fields.
16. The method of claim 8, wherein the EPC technique includes a dose correction, a pattern size bias correction, a pattern shape correction, and a background dose equalization correction.
17. A method of pattering a substrate, the method comprising:
depositing a resist film on a substrate;
exposing the resist film deposited on the substrate by an electron beam writer, wherein the electron beam writer uses electron beam format data based on a dithered integrated circuit (IC) design layout that was generated using vertex information; and
developing the exposed resist film to form a resist pattern on the substrate.
18. The method of claim 17, wherein using electron beam format data based on a dithered integrated circuit (IC) design layout that was generated using vertex information includes:
receiving an IC design layout;
generating a gray map from the IC design layout;
generating a vertex map from the IC design layout;
generating an edge map from the vertex map; and
modifying the IC design layout based on the gray map and the edge map.
19. The method of claim 18, wherein the received IC design layout is an electron proximity correction (EPC) modified IC design layout.
20. The method of claim 18, further comprising using electron beam format data based on the dithered integrated circuit (IC) design layout that was generated using vertex information includes increasing a pixel size of the IC design layout, such that the dithered IC design layout has a larger pixel size than the IC design layout.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A high capacity adenoviral expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and
the transgene,
wherein the polynucleotide is fused to the 3\u2032 end of the transgene and is not translated into an amino acid sequence.
2. The expression vector of claim 1, further comprising an mCMV promoter.
3. The expression vector of claim 2, wherein the mCMV promoter is operably linked to the transgene and the polynucleotide.
4. A method of enhancing the expression of a transgene, comprising:
providing a high capacity adenoviral expression vector comprising: a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene;
introducing the expression vector into a cell; and
maintaining the cell under conditions permitting increased expression of the transgene,
wherein the polynucleotide is fused to the 3\u2032 end of the transgene and is not translated into an amino acid sequence.
5. The method of enhancing the expression of a transgene of claim 4, wherein the cell is maintained in vivo.
6. The method of enhancing the expression of a transgene of claim 4, wherein the cell is maintained in vitro.
7. The method of enhancing the expression of a transgene of claim 4, wherein the expression vector further comprises an mCMV promoter.
8. The method of enhancing the expression of a transgene of claim 7, wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
9. A pharmaceutical preparation, comprising:
a high capacity adenoviral expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene; and
a pharmaceutically acceptable carrier,
wherein the polynucleotide is fused to the 3\u2032 end of the transgene and is not translated into an amino acid sequence.
10. The pharmaceutical preparation of claim 9, wherein the expression vector further comprises an mCMV promoter.
11. The pharmaceutical preparation of claim 10, wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
12. A kit for enhanced expression of a transgene, comprising:
a high capacity adenoviral expression vector, comprising: a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene;
a pharmaceutically acceptable carrier; and
instructions for use,
wherein the polynucleotide is fused to the 3\u2032 end of the transgene and is not translated into an amino acid sequence.
13. The kit for enhanced expression of a transgene of claim 12, wherein the expression vector further comprises an mCMV promoter.
14. The kit for enhanced expression of a transgene of claim 13, wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
15. The kit for enhanced expression of a transgene of claim 12, wherein the kit is configured for in vivo expression of the transgene.
16. The kit for enhanced expression of a transgene of claim 12, wherein the kit is configured for in vitro expression of the transgene.